The China Science and Technology Innovation Board Healthcare ETF Huaxia (588130) saw intraday trading volume exceed 100 million yuan, with an average daily turnover of 145 million yuan over the past week.
" type: "Topics" locale: "en" url: "https://longbridge.com/en/topics/43480173.md" description: "On the afternoon of August 19, the broader market declined, with the Sci-Tech Medical sector showing divergence. As of 14:51, the ChinaAMC Sci-Tech Medical ETF (588130) fell 2.43%. Its holdings saw mixed performance: Tebao Biopharma rose 7.33%, Zeland Pharmaceutical-U gained 2.03%, and Huithai Medical increased by 1.73%, while United Imaging Healthcare dipped 0.31%. However, Hao'oubo and MGI performed poorly, with declines of -8.50% and -7.83% respectively. In terms of liquidity, the ChinaAMC Sci-Tech Medical ETF (588130) recorded a turnover rate of 21.29% and trading volume of RMB 101 million, indicating active market trading..." datetime: "2026-08-19T08:39:58.000Z" locales: - [en](https://longbridge.com/en/topics/43480173.md) - [zh-CN](https://longbridge.com/zh-CN/topics/43480173.md) - [zh-HK](https://longbridge.com/zh-HK/topics/43480173.md) author: "[同壁财经](https://longbridge.com/en/profiles/26505347.md)" generator: "portal-rs" --- #The China Science and Technology Innovation Board Healthcare ETF Huaxia (588130) saw intraday trading volume exceed 100 million yuan, with an average daily turnover of 145 million yuan over the past week.
On the afternoon of August 19, the broader market declined, with the STAR Market Healthcare sector showing divergence. As of 14:51, Huaxia STAR Market Healthcare ETF (588130) fell 2.43%, while its holdings Taibao Biopharmaceutical rose 7.33%, Zeland Pharma-U gained 2.03%, and Hitai Medical increased 1.73%. However, United Imaging Healthcare dropped 0.31%. Meanwhile, Haooubio and MGI performed poorly, falling 8.50% and 7.83% respectively. In terms of liquidity, Huaxia STAR Market Healthcare ETF (588130) saw an intraday turnover rate of 21.29% and trading volume of 101 million yuan, indicating active market participation. Looking at a longer timeframe, as of August 18, the ETF's average daily trading volume over the past week was 145 million yuan, reflecting good liquidity. On the news front, Taibao Biopharmaceutical reported H1 2026 revenue of 1.837 billion yuan (+21.58% YoY) and net profit attributable to shareholders of 477 million yuan (+11.37% YoY), achieving double growth in both revenue and net profit. Significant Q2 performance recovery drove H1 net profit growth. The core product Pegilodecakin achieved sustained sales volume expansion, and the new product Yipeisheng quickly contributed incremental gains after being included in the medical insurance catalog, with a clear trend of product structure upgrading and strong sustainable growth potential. Institutions generally show optimism towards innovative drugs and their supply chains. Guoyuan International noted in its latest research report that the probability of US interest rate hikes is declining, overseas financing is fully recovering, and external demand has significantly improved. The judicial developments regarding WuXi AppTec are favorable for CXO companies to secure new orders overseas. China's innovative drug global expansion continues to exceed expectations, fully validating the global competitiveness of Chinese innovative drug assets. They remain firmly bullish on the industry prospects of the innovative drug supply chain. Huaxia STAR Market Healthcare ETF (588130) provides a convenient tool for low-threshold one-click exposure to the STAR Market Healthcare sector, tracking the SSE STAR Market Bio-Medicine Index. The 20% price limit on the STAR Market offers high elasticity. The index is highly concentrated in three core tracks: chemical pharmaceuticals, medical devices, and biological products, accounting for over 91% of the total weight, helping ordinary investors seize long-term development opportunities in the innovative drug and device sectors. (OTC Feeder A: 027142; Feeder C: 027143). ### Related Stocks - [688266.CN](https://longbridge.com/en/quote/688266.CN.md) - [688617.CN](https://longbridge.com/en/quote/688617.CN.md) - [688271.CN](https://longbridge.com/en/quote/688271.CN.md) - [688656.CN](https://longbridge.com/en/quote/688656.CN.md) - [688114.CN](https://longbridge.com/en/quote/688114.CN.md) - [688278.CN](https://longbridge.com/en/quote/688278.CN.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**